Thanks for the useful links! I think some kind of database with effect sizes, who it works for etc would be really useful. Prioritising between different cognitive enhancers for future research is one of the recommendations I would be excited to see. Avoiding things is something I didn’t consider in much depth but it would be interesting to look into.
George Altman
Karma: 109
Great work! Looking forward to the cause profile
Thanks for your comment. It’s interesting to hear about the similarities between genetic and pharmacological enhancement, such as funding and legal restrictions. The interaction of AGI timelines and pharmacological enhancement is one of the areas where I am least certain. Theoretically, enhancement could speed up the development of AGI and alignment. I’m unsure about the balance of risks and benefits here.